Skip to Content

Generic Phoslyra Availability

Phoslyra is a brand name of calcium acetate, approved by the FDA in the following formulation(s):

PHOSLYRA (calcium acetate - solution;oral)

  • Manufacturer: FRESENIUS MEDCL
    Approval date: April 18, 2011
    Strength(s): EQ 169MG CALCIUM/5ML [RLD]

Has a generic version of Phoslyra been approved?

No. There is currently no therapeutically equivalent version of Phoslyra available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Phoslyra. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Liquid compositions of calcium acetate
    Patent 8,591,938
    Issued: November 26, 2013
    Assignee(s): Lyne Laboratories, Inc.
    The invention relates to an aqueous liquid composition of calcium acetate, sweetener, and taste masking agent. Also provided is a method for binding phosphorus within the gastrointestinal tract of an individual by administering to the individual an aqueous solution of at least calcium acetate.
    Patent expiration dates:
    • February 23, 2030
      ✓ 
      Patent use: USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
      ✓ 
      Drug product
  • Liquid compositions of calcium acetate
    Patent 8,592,480
    Issued: November 26, 2013
    Assignee(s): Lyne Laboratories, Inc.
    The invention relates to an aqueous liquid composition of calcium acetate, sweetener, and taste masking agent. Also provided is a method for binding phosphorus within the gastrointestinal tract of an individual by administering to the individual an aqueous solution of at least calcium acetate.
    Patent expiration dates:
    • July 20, 2027
      ✓ 
      Patent use: USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS
  • Liquid compositions of calcium acetate
    Patent 9,089,528
    Issued: July 28, 2015
    Assignee(s): LYNE LABORATORIES, INC.
    The invention relates to an aqueous liquid composition of calcium acetate, sweetener, and taste masking agent. Also provided is a method for binding phosphorus within the gastrointestinal tract of an individual by administering to the individual an aqueous solution of at least calcium acetate.
    Patent expiration dates:
    • July 20, 2027
      ✓ 
      Patent use: USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide